← Human Trials & Peer-Reviewed Studies
Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial
Plain-language guide to PMID 33831213 (2021): placebo-controlled randomized controlled trial study of Therapeutic nicotine (patch, non-peptide) and Exenatide.
Key Facts
- PMID
- 33831213
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Yammine L et al. (8 authors)
- DOI
- 10.1093/ntr/ntab066
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) and Exenatide in this randomized controlled trial publication.
Glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the rewarding effects of nicotine in preclinical studies.
Who Took Part
Seven-day point prevalence abstinence (expired CO level ≤5 ppm), craving, withdrawal, and post-cessation body weight were assessed following 6 weeks of treatment.
A Bayesian approach for analyzing generalized linear models yielded posterior probabilities (PP) to quantify the evidence favoring hypothesized effects of treatment on the study outcomes.
How the Study Was Run
The design is described as randomized, placebo-controlled and pilot.
The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.
What Was Measured
The subject headings attached to it are Bayes Theorem, Exenatide, Nicotinic Agonists, Pilot Projects, Smoking, Smoking Cessation and Tobacco Use Cessation Devices.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and pilot study of Therapeutic nicotine (patch, non-peptide) and Exenatide.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page and the Exenatide compound page, all human trials.
Our Notes on the Compounds
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.